Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV

NAActive, not recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

May 25, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Vaccination Provision

HPV vaccination #1 will be offered by provider at the first visit when the HPV self-sample is collected. HPV Vaccination #2 will be offered at 6 months for HPV negative women and at 12 months for HPV positive women.

BIOLOGICAL

Vaccination Provision 2

"HPV vaccination #1 will be offered by the provider after an HPV negative result is received with vaccine #2 given at 3 months after negative test results obtained.~For HPV positive women - vaccination #1 will be offered at 12 months and vaccination #2 will be offered at the 15 month mark."

Trial Locations (1)

Unknown

Pamoja Tunaweza Women's Centre, Moshi

All Listed Sponsors
collaborator

Merck Canada Inc.

INDUSTRY

lead

Queen's University

OTHER

NCT06402383 - Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV | Biotech Hunter | Biotech Hunter